In-Young Choi1, Phil Lee2, Abbey J Hughes3, Douglas R Denney3, Sharon G Lynch4. 1. Hoglund Brain Imaging Center and Departments of Molecular & Integrative Physiology and Neurology, University of Kansas Medical Center, Kansas City, KS, USA. 2. Hoglund Brain Imaging Center and Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA. 3. Department of Psychology, University of Kansas, Lawrence, KS, USA. 4. Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract
BACKGROUND: Increased oxidative stress leads to loss of glutathione (GSH). We have reported lower cerebral GSH in patients with secondary progressive multiple sclerosis (SPMS), indicating the involvement of oxidative stress in multiple sclerosis (MS) pathophysiology. OBJECTIVE: This study expanded upon our earlier work by examining longitudinal changes in cerebral GSH in patients with SPMS in relation to their clinical status. METHODS: A total of 13 patients with SPMS (Expanded Disability Status Scale (EDSS) = 4.0-6.5; MS duration = 21.2 ± 8.7 years) and 12 controls were studied over 3-5 years. GSH mapping was acquired from frontal and parietal regions using a multiple quantum chemical shift imaging technique at 3 T. Clinical assessments of the patient's disability included EDSS, gait, motor strength, ataxia, tremor, brainstem function and vision changes. RESULTS: Brain GSH concentrations in patients were lower than those in controls for both baseline and 3- to 5-year follow-ups. Longitudinal GSH changes of patients were associated with their neurologist's blinded appraisal of their clinical progression. Patients judged to have worsening clinical status had significantly greater declines in frontal GSH concentrations than those with stable clinical status. CONCLUSION: GSH provides a distinct measure associated with the disease progression in SPMS, possibly due to its dynamic alignment with pathogenic processes of MS related to oxidative stress.
BACKGROUND: Increased oxidative stress leads to loss of glutathione (GSH). We have reported lower cerebral GSH in patients with secondary progressive multiple sclerosis (SPMS), indicating the involvement of oxidative stress in multiple sclerosis (MS) pathophysiology. OBJECTIVE: This study expanded upon our earlier work by examining longitudinal changes in cerebral GSH in patients with SPMS in relation to their clinical status. METHODS: A total of 13 patients with SPMS (Expanded Disability Status Scale (EDSS) = 4.0-6.5; MS duration = 21.2 ± 8.7 years) and 12 controls were studied over 3-5 years. GSH mapping was acquired from frontal and parietal regions using a multiple quantum chemical shift imaging technique at 3 T. Clinical assessments of the patient's disability included EDSS, gait, motor strength, ataxia, tremor, brainstem function and vision changes. RESULTS: Brain GSH concentrations in patients were lower than those in controls for both baseline and 3- to 5-year follow-ups. Longitudinal GSH changes of patients were associated with their neurologist's blinded appraisal of their clinical progression. Patients judged to have worsening clinical status had significantly greater declines in frontal GSH concentrations than those with stable clinical status. CONCLUSION:GSH provides a distinct measure associated with the disease progression in SPMS, possibly due to its dynamic alignment with pathogenic processes of MS related to oxidative stress.
Entities:
Keywords:
Glutathione; chemical shift imaging; human brain; magnetic resonance spectroscopy; neurodegeneration; oxidative stress; secondary progressive multiple sclerosis
Authors: Fahmy Aboul-Enein; Martin Krssák; Romana Höftberger; Daniela Prayer; Wolfgang Kristoferitsch Journal: PLoS One Date: 2010-07-20 Impact factor: 3.240
Authors: Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: In-Young Choi; Phil Lee; Peter Adany; Abbey J Hughes; Scott Belliston; Douglas R Denney; Sharon G Lynch Journal: Mult Scler Date: 2017-06-01 Impact factor: 6.312
Authors: Muhamed N H Eeza; Rico Singer; Corinna Höfling; Jörg Matysik; Huub J M de Groot; Steffen Roβner; A Alia Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Tyler A Lesh; Richard J Maddock; Amber Howell; Huan Wang; Costin Tanase; J Daniel Ragland; Tara A Niendam; Cameron S Carter Journal: Mol Psychiatry Date: 2019-05-28 Impact factor: 15.992
Authors: Wim Derave; Bert O Eijnde; Jan Spaas; Wouter M A Franssen; Charly Keytsman; Laura Blancquaert; Tim Vanmierlo; Jeroen Bogie; Bieke Broux; Niels Hellings; Jack van Horssen; Dheeraj Kumar Posa; David Hoetker; Shahid P Baba Journal: J Neuroinflammation Date: 2021-11-05 Impact factor: 8.322
Authors: Eric D Vidoni; In-Young Choi; Phil Lee; Gregory Reed; Na Zhang; Joseph Pleen; Jonathan D Mahnken; Jonathan Clutton; Annette Becker; Erica Sherry; Rebecca Bothwell; Heidi Anderson; Robert A Harris; William Brooks; Heather M Wilkins; Lisa Mosconi; Jeffrey M Burns; Russell H Swerdlow Journal: Alzheimers Dement Date: 2020-07-27 Impact factor: 21.566